Cargando…
Healing rate of macular edema secondary to branch retinal vein occlusion in two years after initiation of intravitreal ranibizumab later combined with other treatment as needed and characteristics of refractory cases
PURPOSE: To investigate the 2-year healing rate of macular edema (ME) secondary to branch retinal vein occlusion (BRVO) treated initially with intravitreal ranibizumab (IVR) and later combined with other treatment as needed, and the characteristics of refractory cases. METHODS: 130 patients (130 eye...
Autores principales: | Kawakami, Setsuko, Wakabayashi, Yoshihiro, Watanabe, Yoko, Umazume, Kazuhiko, Yamamoto, Kaori, Goto, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810186/ https://www.ncbi.nlm.nih.gov/pubmed/36595494 http://dx.doi.org/10.1371/journal.pone.0278968 |
Ejemplares similares
-
Comparative Treatment Study on Macular Edema Secondary to Branch Retinal Vein Occlusion by Intravitreal Ranibizumab with and without Selective Retina Therapy
por: Yamamoto, Manabu, et al.
Publicado: (2023) -
Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema
por: Yasuda, Kanako, et al.
Publicado: (2023) -
Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
por: Otawa, Taro, et al.
Publicado: (2022) -
Comment on: Ranibizumab and aflibercept intravitreal injection for treatment
naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020) -
A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Bayat, Alper Halil, et al.
Publicado: (2019)